$1,318.00
This Market Spotlight report covers the Systemic Hypertension market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Systemic Hypertension market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 Pharmacological therapy
10 EPIDEMIOLOGY
14 MARKETED DRUGS
30 PIPELINE DRUGS
35 RECENT EVENTS AND ANALYST OPINION
35 KBP-5074 for Systemic Hypertension (December 4, 2020)
37 KEY UPCOMING EVENTS
38 KEY REGULATORY EVENTS
38 Novartis’s Entresto Receives Approval For Hypertension In China
39 PROBABILITY OF SUCCESS
40 REVENUE OPPORTUNITY
44 CLINICAL TRIAL LANDSCAPE
45 Sponsors by status
46 Sponsors by phase
47 Recent events
49 BIBLIOGRAPHY
50 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of systemic hypertension, 2017–26
30 Figure 2: Overview of pipeline drugs for systemic hypertension in the US
30 Figure 3: Pipeline drugs for systemic hypertension, by company
31 Figure 4: Pipeline drugs for systemic hypertension, by drug type
31 Figure 5: Pipeline drugs for systemic hypertension, by classification
36 Figure 6: KBP-5074 for Systemic Hypertension (December 4, 2020): Phase IIb – BLOCK-CKD
37 Figure 7: Key upcoming events in systemic hypertension
39 Figure 8: Probability of success in the systemic hypertension pipeline
44 Figure 9: Clinical trials in hypertension
44 Figure 10: Top 10 drugs for clinical trials in hypertension
45 Figure 11: Top 10 companies for clinical trials in hypertension
45 Figure 12: Trial locations in hypertension
46 Figure 13: Hypertension trials status
47 Figure 14: Hypertension trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of systemic hypertension (000s), 2017–26
13 Table 2: Prevalent cases of systemic hypertension (000s), by gender, 2017
15 Table 3: Marketed drugs for systemic hypertension
32 Table 4: Pipeline drugs for systemic hypertension in the US
35 Table 5: KBP-5074 for Systemic Hypertension (December 4, 2020)
41 Table 6: Historical global sales, by drug ($m), 2017–21
43 Table 7: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!